The cytoplasmic site of gene expression and use of virally encoded enzymes are distinguishing features of vaccinia virus and other poxvirus vectors that contribute to their consistent ability to express genes derived from a variety of prokaryotic, eukaryotic and viral sources. This feature, together with their ability to stably integrate and package large amounts of additional DNA, and broad host range, account for their general use as a research tool and for synthesis of recombinant proteins in mammalian cells. Recombinant vaccinia viruses are also being tested as live vaccines. During the past year, we continued to evaluate the highly attenuated modified vaccinia virus Ankara (MVA) strain as a safe vector in the laboratory and as a vector for candidate vaccines against infectious diseases and cancers

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000298-20
Application #
6506802
Study Section
(LVD)
Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Domi, Arban; Moss, Bernard (2002) Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A 99:12415-20
Stittelaar, K J; Kuiken, T; de Swart, R L et al. (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700-9
McCart, J A; Ward, J M; Lee, J et al. (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61:8751-7
Hu, Y; Lee, J; McCart, J A et al. (2001) Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J Virol 75:10300-8
Zhu, Y d; Rota, P; Wyatt, L et al. (2000) Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276:202-13
Stittelaar, K J; Wyatt, L S; de Swart, R L et al. (2000) Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 74:4236-43
Men, R; Wyatt, L; Tokimatsu, I et al. (2000) Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18:3113-22
Wyatt, L S; Whitehead, S S; Venanzi, K A et al. (1999) Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18:392-7
Durbin, A P; Cho, C J; Elkins, W R et al. (1999) Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 J Infect Dis 179:1345-51
Nam, J H; Wyatt, L S; Chae, S L et al. (1999) Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine 17:261-8